Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation

Y. Tanaka, S. Kurosawa, K. Tajima, T. Tanaka, R. Ito, Y. Inoue, K. Okinaka, Y. Inamoto, S. Fuji, S. W. Kim, Ryuji Tanosaki, T. Yamashita, T. Fukuda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has curative potential against hematological malignancies. However, there are concerns about the associated risk of non-relapse mortality (NRM). We performed a retrospective single-center study to assess changes in outcomes after allo-HSCT and causes of NRM over three 5-year periods. The rates of 2-year NRM and overall survival (OS) were 16% and 59%, respectively. We found a significant decrease in NRM (P<0.001), with 2-year NRM of 26, 14 and 9%, and a significant increase in OS (P=0.005), with 2-year OS of 52%, 58% and 65%, over the three periods (1998-2002, 2003-2007 and 2008-2012), respectively. Of note, a steady improvement was observed in NRM, period by period, among patients aged 50 years or older, patients who underwent HSCT from an unrelated bone marrow donor and patients who underwent HSCT with a reduced-intensity conditioning regimen. Our data showed that the improved NRM can mainly be attributed to a decreased mortality related to infection after starting systemic steroid as GVHD treatment, and a decreased mortality related to organ failure.

Original languageEnglish
Pages (from-to)553-559
Number of pages7
JournalBone Marrow Transplantation
Volume51
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Cause of Death
Mortality
Survival
Hematologic Neoplasms
Bone Marrow
Steroids
Tissue Donors
Infection

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. / Tanaka, Y.; Kurosawa, S.; Tajima, K.; Tanaka, T.; Ito, R.; Inoue, Y.; Okinaka, K.; Inamoto, Y.; Fuji, S.; Kim, S. W.; Tanosaki, Ryuji; Yamashita, T.; Fukuda, T.

In: Bone Marrow Transplantation, Vol. 51, No. 4, 01.04.2016, p. 553-559.

Research output: Contribution to journalArticle

Tanaka, Y, Kurosawa, S, Tajima, K, Tanaka, T, Ito, R, Inoue, Y, Okinaka, K, Inamoto, Y, Fuji, S, Kim, SW, Tanosaki, R, Yamashita, T & Fukuda, T 2016, 'Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation', Bone Marrow Transplantation, vol. 51, no. 4, pp. 553-559. https://doi.org/10.1038/bmt.2015.330
Tanaka, Y. ; Kurosawa, S. ; Tajima, K. ; Tanaka, T. ; Ito, R. ; Inoue, Y. ; Okinaka, K. ; Inamoto, Y. ; Fuji, S. ; Kim, S. W. ; Tanosaki, Ryuji ; Yamashita, T. ; Fukuda, T. / Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. In: Bone Marrow Transplantation. 2016 ; Vol. 51, No. 4. pp. 553-559.
@article{3811216b71004c239968ea1704735971,
title = "Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has curative potential against hematological malignancies. However, there are concerns about the associated risk of non-relapse mortality (NRM). We performed a retrospective single-center study to assess changes in outcomes after allo-HSCT and causes of NRM over three 5-year periods. The rates of 2-year NRM and overall survival (OS) were 16{\%} and 59{\%}, respectively. We found a significant decrease in NRM (P<0.001), with 2-year NRM of 26, 14 and 9{\%}, and a significant increase in OS (P=0.005), with 2-year OS of 52{\%}, 58{\%} and 65{\%}, over the three periods (1998-2002, 2003-2007 and 2008-2012), respectively. Of note, a steady improvement was observed in NRM, period by period, among patients aged 50 years or older, patients who underwent HSCT from an unrelated bone marrow donor and patients who underwent HSCT with a reduced-intensity conditioning regimen. Our data showed that the improved NRM can mainly be attributed to a decreased mortality related to infection after starting systemic steroid as GVHD treatment, and a decreased mortality related to organ failure.",
author = "Y. Tanaka and S. Kurosawa and K. Tajima and T. Tanaka and R. Ito and Y. Inoue and K. Okinaka and Y. Inamoto and S. Fuji and Kim, {S. W.} and Ryuji Tanosaki and T. Yamashita and T. Fukuda",
year = "2016",
month = "4",
day = "1",
doi = "10.1038/bmt.2015.330",
language = "English",
volume = "51",
pages = "553--559",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation

AU - Tanaka, Y.

AU - Kurosawa, S.

AU - Tajima, K.

AU - Tanaka, T.

AU - Ito, R.

AU - Inoue, Y.

AU - Okinaka, K.

AU - Inamoto, Y.

AU - Fuji, S.

AU - Kim, S. W.

AU - Tanosaki, Ryuji

AU - Yamashita, T.

AU - Fukuda, T.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has curative potential against hematological malignancies. However, there are concerns about the associated risk of non-relapse mortality (NRM). We performed a retrospective single-center study to assess changes in outcomes after allo-HSCT and causes of NRM over three 5-year periods. The rates of 2-year NRM and overall survival (OS) were 16% and 59%, respectively. We found a significant decrease in NRM (P<0.001), with 2-year NRM of 26, 14 and 9%, and a significant increase in OS (P=0.005), with 2-year OS of 52%, 58% and 65%, over the three periods (1998-2002, 2003-2007 and 2008-2012), respectively. Of note, a steady improvement was observed in NRM, period by period, among patients aged 50 years or older, patients who underwent HSCT from an unrelated bone marrow donor and patients who underwent HSCT with a reduced-intensity conditioning regimen. Our data showed that the improved NRM can mainly be attributed to a decreased mortality related to infection after starting systemic steroid as GVHD treatment, and a decreased mortality related to organ failure.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has curative potential against hematological malignancies. However, there are concerns about the associated risk of non-relapse mortality (NRM). We performed a retrospective single-center study to assess changes in outcomes after allo-HSCT and causes of NRM over three 5-year periods. The rates of 2-year NRM and overall survival (OS) were 16% and 59%, respectively. We found a significant decrease in NRM (P<0.001), with 2-year NRM of 26, 14 and 9%, and a significant increase in OS (P=0.005), with 2-year OS of 52%, 58% and 65%, over the three periods (1998-2002, 2003-2007 and 2008-2012), respectively. Of note, a steady improvement was observed in NRM, period by period, among patients aged 50 years or older, patients who underwent HSCT from an unrelated bone marrow donor and patients who underwent HSCT with a reduced-intensity conditioning regimen. Our data showed that the improved NRM can mainly be attributed to a decreased mortality related to infection after starting systemic steroid as GVHD treatment, and a decreased mortality related to organ failure.

UR - http://www.scopus.com/inward/record.url?scp=84954553501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954553501&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.330

DO - 10.1038/bmt.2015.330

M3 - Article

C2 - 26752142

AN - SCOPUS:84954553501

VL - 51

SP - 553

EP - 559

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -